Elinzanetant Shows Promise for Sleep Disturbances in Postmenopausal Women

Elinzanetant, a non-hormonal neurokinin-1 and 3 receptor antagonist, significantly improves sleep disturbances in postmenopausal women experiencing vasomotor symptoms, according to post-hoc analyses of the phase 3 OASIS clinical trial program. Data presented at the 2024 SLEEP annual meeting indicate that the medication addresses sleep fragmentation and sleep-related impairment directly, rather than solely as a secondary effect of reducing hot flashes.

How Elinzanetant Affects Sleep Quality

The primary mechanism of elinzanetant involves modulating the KNDy neurons in the hypothalamus, which are implicated in both thermoregulation and sleep-wake cycles. According to the Bayer-sponsored OASIS 1 and 2 trials, participants reported meaningful improvements in sleep quality within the first week of treatment. Unlike traditional hormone replacement therapy, which replaces estrogen, elinzanetant works by blocking specific receptors to quiet the neural pathways that trigger both nighttime vasomotor symptoms—commonly known as night sweats—and the subsequent disruption of the sleep architecture.

Comparison of Treatment Approaches

Postmenopausal sleep disturbances are traditionally managed through lifestyle modifications, hormone therapy, or off-label use of sleep aids. The following table highlights the differences in therapeutic approaches for these symptoms:

While hormone therapy remains the gold standard for many, the New England Journal of Medicine published findings showing that non-hormonal alternatives like elinzanetant provide a critical option for women who have contraindications to hormone use, such as a history of estrogen-sensitive cancers or cardiovascular risk factors.

Clinical Significance of the OASIS Findings

The clinical importance of these findings lies in the distinction between symptom relief and sleep restoration. Researchers noted that even when vasomotor symptoms were controlled, sleep quality did not always return to baseline in previous studies of other agents. However, the OASIS data suggest that elinzanetant’s dual action on NK1 and NK3 receptors provides a more comprehensive benefit for sleep-related impairment. By targeting the neural circuits that regulate both the body’s internal thermostat and the sleep-wake state, the drug helps stabilize the circadian disruption often reported during the menopausal transition.

Frequently Asked Questions

Is elinzanetant currently available for prescription?

As of late 2024, elinzanetant is undergoing regulatory review by the U.S. Food and Drug Administration (FDA) and other international health authorities. It is not yet available for general clinical use.

How does this differ from fezolinetant?

Fezolinetant (Veozah) is a selective NK3 receptor antagonist currently FDA-approved for the treatment of moderate to severe vasomotor symptoms. Elinzanetant is a dual NK1 and NK3 receptor antagonist, which researchers hypothesize may offer broader therapeutic benefits for sleep and mood symptoms associated with menopause.

What are the common side effects observed in trials?

According to the Bayer clinical program data, the most frequently reported side effects in the OASIS trials included headache and fatigue. Serious adverse events remained low, consistent with the safety profiles observed in similar neurokinin antagonist studies.

Future Outlook

The medical community continues to await long-term safety data from the ongoing open-label extension studies of the OASIS program. If approved, elinzanetant would represent a new class of medication specifically designed to address the multifaceted nature of menopausal symptoms, moving beyond the singular focus on hot flashes to include the broader impact on patient quality of life and sleep health.